Thiazolidinedione Derivatives in Type 2 Diabetes Mellitus

Overview

Journal Neth J Med

Specialty General Medicine

Date 2006 Jun 22

PMID 16788214

Citations 4

Authors

C J J Tack

P Smits

Affiliations

Soon will be listed here.

Abstract

In Europe, the thiazolidinedione derivatives pioglitazone and rosiglitazone have been approved for the treatment of type 2 diabetes mellitus either as monotherapy for patients with intolerance or contraindications to metformin or in combination therapy. This class of drugs seems particularly suited for obese patients, but is currently not considered as a first choice for monotherapy. The efficacy with respect to blood glucose lowering is comparable with sulphonylurea (SU) derivatives and with metformin. Long-term data with respect to efficacy and side effects are still limited.

Citing Articles

Electrochemical Assays for the Determination of Antidiabetic Drugs-A Review.

Fendrych K, Gorska-Ratusznik A, Smajdor J Micromachines (Basel). 2024; 15(1).

PMID: 38276837 PMC: 10820374. DOI: 10.3390/mi15010010.

Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus.

Blahova J, Martiniakova M, Babikova M, Kovacova V, Mondockova V, Omelka R Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451903 PMC: 8398612. DOI: 10.3390/ph14080806.

Testing the ability of rhodanine and 2, 4-thiazolidinedione to interact with the human pancreatic alpha-amylase: electron-density descriptors complement molecular docking, QM, and QM/MM dynamics calculations.

Devi R, Khrenova M, Israel S, Anzline C, Astakhov A, Tsirelson V J Mol Model. 2017; 23(9):252.

PMID: 28780749 DOI: 10.1007/s00894-017-3418-5.

Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus.

Tran M, Delate T, Bachmann S Pharm Pract (Granada). 2014; 6(2):79-87.

PMID: 25157285 PMC: 4141869. DOI: 10.4321/s1886-36552008000200004.